Besilesomab

N/A

Report date: 2025/09/04 17:54:11
First In Class

Base Information

Drug NameBesilesomab
Drug Alias Name贝索单抗Technetium-99m-antigranulocyte antibody BW 250-183Tc 99m-labeled monoclonal antibody BW 250/183贝西来索单抗(99m)Tc-besilesomab +[13] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive diagnostic agent +[5] 
Mechanisms of ActionAnti-NCA-95Single-photon emission-computed tomography enhancers
TargetsNon specific cross-reacting antigen 95
Therapy Area/IndicationsOsteomyelitis
Global Approved IndicationsOsteomyelitis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryEU
Original Approved Date2010/01/11
Country/TerritoryEU
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesCis Bio International Sa
China Registration ClassN/A

Develop Information

Active CompaniesCis Bio International SaTelix Pharmaceuticals Ltd
Inactive CompaniesN/A
Active IndicationsOsteomyelitis
Inactive IndicationsN/A

Other Information

ATC CodeV09HA03
Related LinksWikipedia